Company page

Cytomx Therapeutics, Inc.

Cytomx Therapeutics, Inc. (ticker: CTMX) is a public company based in the United States with a market capitalization of approximately $642.2 million. The company focuses on developing innovative cancer therapies using its proprietary Probody™ technology platform. Cytomx aims to improve treatment options for patients by targeting tumors while minimizing damage to healthy tissue.